Galapagos moves AbbVie-partnered drug into PhI as multipronged attack on CF takes shape

Nick Paul Taylor

has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) , GLPG2222. The start of the trial marks another milestone in the rolling advance of Galapagos' on CF, which is set to be bolstered later this year by the emergence of more next-generation correctors.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS